M&S Biotics, Inc

14% of the operative time is spent counting surgical sponges alone (no metal instruments) because this is manually done it leads to 1 in 8 surgeries having a counting discrepancy. This leads to more time and risk for the patient. Worse yet, less than 20% of the instruments brought into the operating room are even utilized through the course of the procedure.

M&S Biotics is a 510k Class 1 (exempt) medical device and is currently in our soft launch phase, with our first pilot kicking off in 2023. • M&S Biotics secured a partnership with AT&T and will deploy our product to their healthcare accounts. o The first account is through the Veterans Healthcare Administration (VHA), starting with a fully paid pilot ($120,000) at Puget Sound, Washington. • We are registered as a 510k Class 1 (exempt) device. o Direct Sales and Co-Sale via AT&T • M&S Biotics secured a partnership with AT&T and will deploy our product (co-sale) to their healthcare accounts. o The first account is through the Veterans Healthcare Administration (VHA), starting with a fully paid pilot ($120,000) at Puget Sound, Washington. o Three additional sites are in the process. • IP- One PCT patent pending with a plan to file three more in 2023. • Our Phase 1 NIH (NCATS) grant for $255,719 led to a publication in the IEEE journal: https://ieeexplore.ieee.org/document/9851422 • M&S Biotics is the first U.S Based Medical Device Company to partner with Johnson and Johnson’s Center for Device Innovation. • M&S Biotics is a vendor through Health Trust Purchasing Group (HPG). A Group Purchasing Organization that sells to 1,400 hospitals. • M&S Biotics has raised $2.6M in grants, capital, and competition prizes to get us to this stage, and we are currently targeting a Series A raise in 2023.

• M&S Biotics | Company | Mindmaps

  mindmaps.ai-ecosystem.org